IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10077247 B1

PDFFull Text
Date of Patent:
Sep. 18, 2018

Filed:

Jan. 08, 2016

Tricyclic spiro compound

Applicant:

Ono Pharmaceutical Co., Ltd., Osaka, JP;

Inventors:

Masaki Asada, Osaka, JP;

Kousuke Tani, Osaka, JP;

Masaya Hirobe, Osaka, JP;

Satonori Higuchi, Osaka, JP;

Kazuhiro Fuchibe, Osaka, JP;

Ryo Oikawa, Osaka, JP;

Tohru Kotani, Osaka, JP;

Hirotsugu Takano, Osaka, JP;

Assignee:

ONO PHARMACEUTICAL CO., LTD., Osaka, JP;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Samira J Jean-Louis

Int. Cl.
CPC ...
C07D 311/96 (2006.01); C07D 405/14 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61K 31/277 (2006.01); A61K 31/343 (2006.01); A61K 31/352 (2006.01); A61K 31/381 (2006.01); A61K 31/397 (2006.01); A61K 31/4025 (2006.01); A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 31/4192 (2006.01); A61K 31/422 (2006.01); A61K 31/4245 (2006.01); A61K 31/427 (2006.01); A61K 31/437 (2006.01); A61K 31/4406 (2006.01); A61K 31/4433 (2006.01); A61K 31/4439 (2006.01); A61K 31/453 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/5383 (2006.01); A61K 33/24 (2006.01); C07C 255/63 (2006.01); C07D 307/94 (2006.01); C07D 231/12 (2006.01); C07D 405/12 (2006.01); C07D 407/12 (2006.01); C07D 409/12 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 498/04 (2006.01); C07D 213/56 (2006.01); A61K 9/20 (2006.01); A61K 31/4427 (2006.01); A61K 31/496 (2006.01); A61K 45/06 (2006.01); C07C 255/60 (2006.01); C07D 213/40 (2006.01); C07D 231/40 (2006.01); C07D 401/04 (2006.01); C07D 405/04 (2006.01); C07D 409/04 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01);
U.S. Cl.
CPC ...
C07D 311/96 (2013.01); A61K 9/20 (2013.01); A61K 31/277 (2013.01); A61K 31/343 (2013.01); A61K 31/352 (2013.01); A61K 31/381 (2013.01); A61K 31/397 (2013.01); A61K 31/4025 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/4192 (2013.01); A61K 31/422 (2013.01); A61K 31/427 (2013.01); A61K 31/4245 (2013.01); A61K 31/437 (2013.01); A61K 31/4406 (2013.01); A61K 31/4427 (2013.01); A61K 31/4433 (2013.01); A61K 31/4439 (2013.01); A61K 31/453 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/5383 (2013.01); A61K 33/24 (2013.01); A61K 39/395 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); C07C 255/60 (2013.01); C07C 255/63 (2013.01); C07D 213/40 (2013.01); C07D 213/56 (2013.01); C07D 231/12 (2013.01); C07D 231/40 (2013.01); C07D 307/94 (2013.01); C07D 401/04 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 407/12 (2013.01); C07D 409/04 (2013.01); C07D 409/12 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 417/04 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 498/04 (2013.01); C07C 2603/94 (2017.05);
Abstract

A medicinal agent for the prevention and/or treatment of diseases caused by EPreceptor activation. A compound having antagonistic activity against the EPreceptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EPreceptor for the prevention and/or treatment of diseases caused by EPreceptor activation.

Find Patent Forward Citations

Loading…